SAS Output

14-DEC-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 0 0 0 0 0 BREAST
        9383 0 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 0 0 0 0 0  
      3 Endocrine Therapy Alone 2536 0 0 0 0 0  
        5083 0 0 0 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 896 182 88 49 19 6 BREAST
      2 Blinded drug + Endocrine 901 177 84 42 16 4  
        1797 359 172 91 35 10  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 7 3 2 2 0 0 SURV
      2 Randomization Non-surgical M 8 4 3 2 1 0  
      3 Patient Choice Surgery 54 17 9 5 0 0  
      4 Patient Choice Non-surgical M 100 16 0 0 0 0  
        169 40 14 9 1 0  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 612 251 112 62 19 7 CCD
      2 Site randomized: Control 443 204 111 66 30 7  
      3 SiteRand Int Risk: CSF 761 428 171 97 37 7  
      4 SiteRand Int Risk: No CSF 617 356 176 101 39 8  
        2433 1239 570 326 125 29  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 351 208 90 53 15 6 CCD
        351 208 90 53 15 6  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 387 265 147 82 31 13 BREAST
        387 265 147 82 31 13  
 
  2 Y 2 Observation 159 103 54 26 10 2  
      3 MK-3475 (Pembrolizumab) 160 113 58 29 13 0  
        319 216 112 55 23 2  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 62 59 48 28 8 5 SURV
        62 59 48 28 8 5  
 
  2 Y 1 Carvedilol 11 10 9 4 1 1  
      2 No prophylaxis 11 10 8 6 0 0  
      3 Observation 30 29 21 14 4 0  
        52 49 38 24 5 1  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 66 47 30 12 5 0 GU
      2 Tokyo-172 BCG 67 48 31 15 7 1  
      3 Prime + Tokyo-172 BCG 66 47 28 16 6 2  
        199 142 89 43 18 3  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 8 8 8 8 2 0 CCD
        8 8 8 8 2 0  
 
  2 Y 1 Control (Usual Care) 1 1 1 1 1 0  
      2 Intervention (STMDDM) 1 1 1 1 0 0  
        2 2 2 2 1 0  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 22 22 22 22 6 0 GU
        22 22 22 22 6 0  
 
  2 Y 1 Standard Systemic Therapy Only 4 4 4 4 1 1  
      2 SST + Surgery/RT 4 4 4 4 1 0  
        8 8 8 8 2 1  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 511 75 18 12 6 1 PREV
        511 75 18 12 6 1  
 
  1 Y 1 Blinded drug 76 28 15 8 3 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 76 24 11 4 2 1  
        223 52 26 12 5 1